#CRLBF

[impact-newswire]

Cresco Labs Announces Dennis Olis to Retire as Chief Financial Officer

Taps BJs Wholesale Club Executive Sharon Schuler for Planned Transition Financial executive Sharon Schuler joins Cresco Labs and will succeed retiring CFO Dennis Olis (Photo: Business Wire) CHICAGO – Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the…

[newsletterdrafts]

3 Tempting Mistakes to Avoid if There's a New Bull Market in 2023

Your portfolio's long-term health is at stake even when the market is rising. https://www.fool.com/investing/2022/12/16/3-tempting-mistakes-to-avoid-if-theres-a-new-bull/

[otcwiki]

CRLBF

Connect to the OTC Wiki and learn all about the Cresco Labs. This firm conducts its business operations and ensures efficiency in service delivery together with its subsidiaries. The company offers quality, consistent, and approachable cannabis products tailored to the customer's needs. Moreover, the company presents the common stock under the name CRLBF Stock.

[wealthyvc]

+ Technical Chart and Technical Analysis Signal (Buy, Strong Buy, Neutral, Sell, Strong Sell).

Join the TCI Investor Network:

🇺🇸 USA: Text potstocks to 313131 to join

🇨🇦️ CDN: Text potstocks to 393939 to join

Subscribe to email newsletter: https://bit.ly/2Zkseth

[thepoetoaster]

Making good on my word & investing the extra $200 I was going to spend at lululemon into the stock market 😆 Tips for investing for beginners: •get an e-trade account •the overall trend of the stock market is upwards so you’re almost guaranteed to make money if you can be patient and stick with it for the long term •try starting off by investing in things that you love or are interested in or a cause you care you about!!! I’m going to use these funds to buy vegan (BYND) & marijuana (CRLBF) stocks LOL. Make it fun, investing doesn’t have to be boring!!! Investing is the key to all true wealth & it’s why the rich get richer. It’s an atrocity they don’t teach about finance & investing in the school system. Don’t get me started. It’s something you need to self-educate on or find someone who’s a financial guru and learn from them. Maybe once I master it I can make a course about it, Lord knows this knowledge is needed 😎 It’s better to BE rich than to look rich so consider investing in stocks or crypto instead of in that fancy handbag or expensive watch or whatever. I’m not saying deprive yourself, sometimes the joy these material things bring can be considered an investment!! But very often people buy them just to show off or impress other people and it doesn’t actually bring them any real fulfillment. Hope this is helpful & inspiring!!! 💓 #stocks #investing #crypto #bitcoin #invest #money #wealth #freedom #entrepreneur #stockmarket #business #finance #lawofattraction #manifestation #abundance #gratitude (at Hulbert Library of the Town of Concord) https://www.instagram.com/p/CVxuxa2LAf2/?utm_medium=tumblr

[fortheloveofluxuryxo]

WEED STONKS 🍁💸

YOUTUBE EPISODE

It feels very good to be apart of the wave on innovation in cannabis, crypto, and tech as a whole. I've worked in the cannabis industry for 7 years in a range of jobs - retail/marketing, cultivation, extractions, media - and am now reasearching investing into cannabis stocks. REAL HIGH STONKS potential! There is so much potential for cannabis, it's an incredible herb, and we are only getting started.

I have experienced a small sliver of California go through its legislation phases from the last years of prop 215 (2014), legal medical marijuana, to prop 64 (2016), adult recreational use. Now we have multiple states in the US little by little working on legalization and decriminalization, with New York as the recent state to do so, despite still being federally illegal. Although it can be very enjoyable as a leisure activity, cannabis isn't just a recreational herb, it's a form of healing for a lot of others as cannabis can be consumed in so many ways aside from smoking flower, and the plant has an incredible range of cannabinoids and terpene profiles that can be curated to optimum levels for each person who wants to treat a certain ailment (for example - CBD, CBN, Delta-9 THC, Delta-8 THC, etc). With that said, not only are there medicinal + lifestyle benefits, there is big wealth potential on investing in the cannabis industry within the stock market in the next years to come.

There are a few publically traded American cannabis companies available on the market here in the US and a few others I'm keeping my eye on located in Canada.

Top 10 watch list + ticker 1. Cresco (Illinois) - CRLBF 2. Trulieve (Florida) - TCNNF 3. MedMen (California) - MMNWF 4. Planet 13 (Nevada) - PLNHF 5. Curaleaf Holdings (Massachusetts) - CURLF 6. KushCo Holdings (California) - KSHB 7. Acreage Holdings (Canada & currently running business in New York) - ACRDF 8. Sundial Growers (Canada) - SNDL 9. Aphria (Canada) - APHA 10. Cronos (Canada) - CRON

As news and market movement continues, I anticipate on seeing more activity with these companies. I have also kept my eye on psilocybin stocks and expect to see some movement with that, a slow progression towards drug decriminalization as a whole. I look forward to more focus on decrimininalization with the expunging of records and release of those incriminated by non-violent possesion and sales of marijuana. I also look forward to seeing more black and brown folks create generational wealth with cannabis (and hemp) as the years progress as there are so many sectors in cannabis that can accumulate ample wealth. Cannabis is for the culture, for all. Although legalization news is exciting, it simply isn't enough if it isn't going to be accessible to everyone.

As always, this is not financial advice, just me talking about things I find interesting and as an ideal opportunity for what I'm involved in. Cannabis ignites my solarpunk fantasies into a closer reality! We love to see it! Do your own research. There is a risk in investing, never invest more than you're willing to lose. Happy earning!

More reading What’s New With Cannabis Stocks for the Week Ending 04/02/21 - New Cannabis Ventures Top Marijuana Stocks - Investopedia Cannabis & Psychadelics - Benzinga

[ericvick]

Wall Street forecasts just keep going up: Morning Brief

TipRanks

3 U.S. Cannabis Stocks Gearing up for Growth; Cantor Says ‘Buy’

At the end of 2018, Canada fully legalized cannabis, nationwide, for both medical and recreational use. With the incoming Biden Administration, the US is expected to follow suit with Federal-level legalization, or at least formal decriminalization, sometime in the next four years. An exact timetable is impossible to predict; much will depend on the partisan makeup of Congress after the Georgia Senate runoff vote in early January.For now, cannabis legalization in the US is something of a checkerboard. Most states have at least partial legalization, with only Idaho and Nebraska holding out. Eleven states have made cannabis fully legal for all adults; the remaining 37 states have some form of partial medical use, and even Nebraska has decriminalized the substance. Under Federal law, cannabis remains an illegal controlled substance.Cantor analyst Pablo Zuanic recently met with several cannabis industry execs and came back with a few takeaways.”[The] speakers believe that under a Biden WH and Republican-controlled Senate, banking reform would pass in early 2021 and would be included in a COVID relief package […] In general, both speakers believe measured progression in legislation is the best path at the federal level, and expect a version of the STATES act (making cannabis federally permissible) to pass the Senate post the next midterms (this could take place sooner in the event of a 50-50 Senate split and a Biden WH). Other changes (descheduling, federal legalization) may take longer,” Zuanic noted.Prepping for the possible changes, Zuanic has also been reviewing several cannabis stocks operating in the American market. Using the TipRanks database, we’ve pulled up the stats on three such stocks, which show the classic ‘growth stock’ profile: plenty of upside potential, recent strong share appreciation, and a Strong Buy rating from the analyst consensus. Curaleaf (CURLF)We’ll start with Curaleaf which, with a $7.7 billion market cap, is one of the largest cannabis companies around. By revenue, Curaleaf is the world’s largest cannabis producer, a position it cemented with the acquisition, earlier this year, of private competitor Grassroots. Curaleaf has operations in 23 states, including 30 processing facilities, 88 dispensaries, and 134 dispensary licenses. Curaleaf grows its product in 22 cultivation sites, with a combined 1.6 million square feet of cultivation capacity.Curaleaf’s performance this year, both in financial results and share appreciation, show the potential of the cannabis market in the US. The company reported $193.2 million in Q3 revenue, for a 59% sequential gain and even more impressive 164% year-over-year growth. The gains were powered by retail revenue, which grew 3x year-over-year to 135.3 million and wholesale revenue, which saw a massive 7x yoy gain to $45 million. While Curaleaf reported a net loss for Q3, that loss was only 1 cent per share, where analysts had expected twice that amount.Curaleaf shares are up 85% year-to-date. While trading in the company has been volatile, it has regained all of its COVID related losses from last winter.Covering this stock for Cantor, Zuanic writes, “We believe the company’s scale advantage, ability to raise funds ($1Bn shelf), and continued store and cultivation expansion, all warrant a valuation premium to peers… [Curaleaf] did not provide guidance for 2021, but the assumption is that it would post growth over the $1Bn annualized figure with which it will likely exit 2020.”Backing this bullish stance, Zuanic gives the stock an Overweight (i.e. Buy) rating, and his $20 price target suggests it has room for 71% growth in 2021. (To watch Zuanic’s track record, click here)Overall, CURLF shares get a Strong Buy rating from the analyst consensus, based on an 8 to 1 mix of Buy versus Hold reviews. The shares are trading at $11.69, and their $14.87 average price target implies a one-year upside potential of 27%. (See Curaleaf stock analysis on TipRanks)Green Thumb (GTBIF)Green Thumb is a Canadian company that has been expanding its foothold in the US market. While Canada’s nationwide legalization regime gives it an advantage over the fragmented, the US is a far larger market, with nearly 10x Canada’s population. Green Thumb’s products include edibles, pre-rolled joints, and vapes, along with a range of CBD-infused wellness items aimed at the home healthcare market. In the past two months, the company’s market cap has expanded from $3.3 billion to $4.6 billion.That market cap growth has been fueled by a massive share appreciation. GTBIF bottomed out in March, at the height of the coronavirus crisis, and is up 426% since then. Year-to-date, the stock is up 120%.That share growth, in turn, has been powered by strong revenues through 2020. In fact, Green Thumb’s Q1 top line showed a 35% sequential gain, at a time when many companies were registering quarter-over-quarter losses. GTBIF has continued to growth revenues since then, with Q3’s top line coming in at $157.1 million, up 131% year-over-year and 31% from Q2. These strong revenues yielded a Q3 EPS of 4 cents per share, derived from total net income of $9.6 million.In his note on Green Thumb, Zuanic reiterates his Overweight (i.e. Buy) rating, and sets a price target of $35 to indicate a 62% upside in the coming year.Backing his outlook, Zuanic writes, “We estimate that there is at least 20% upside to 2021 consensus sales estimates […] Given the profitability trackrecord, growth potential, and franchise strength, we think valuation multiples well above CPG stocks would be deserved (CPG multiples are ~20x EBITDA on average). Also, with federal permissibility still 2-4 years out, the larger MSOs have a window before CPG or the larger Canadian companies (the well-funded ones) can get involved in the US market in a major way. All this should be factored into the stock’s valuation.”Overall, Green Thumb has a unanimous analyst consensus rating, showing that Wall Street agrees with Zuanic’s views. The stock has no fewer than 8 Buy reviews in recent weeks. The average price target is $30.81, which suggests a 43% upside potential. (See Green Thumb’s stock analysis on TipRanks)Cresco Labs (CRLBF)Last but not least is Cresco Labs, a Chicago-based cannabis company with operations in the medical marijuana sector. The company markets its products in retail stores under the Sunnyside* brand, with licenses in 6 states: Arizona, Illinois, Massachusetts, New York, Ohio, and Pennsylvania. Cresco full product line-up includes eight other brand names, offering everything from buds, joints, and edibles to vapes and gummies. Counting all production facilities, retail licenses, and operational dispensaries, Cresco has a presence in 9 states.Cresco has shown strong growth in 2020. The stock is up 48% year-to-date, and there are still another three weeks of trading before year’s end. The gains have fully erased losses taken early in the COVID pandemic.Cresco has posted Q3 revenues of $153.3 million, a company quarterly record. The top line result was $59 million higher than the previous quarter, for a 63% sequential gain. The revenues rested on a foundation of strong retail sales, which totaled $90.5 million in the quarter. Cresco’s quarterly earnings are up from $66.4 million in Q1, a 130% gain year-to-date.Pablo Zuanic notes the company’s retail success in his note on the stock. He says, “Cresco beat our above consensus sales estimate by 23% on market share gains in wholesale in states like IL, PA, and CA, and continued IL retail outperformance… The branded wholesale model (near 60% of sales vs. 25% at peers) and depth (leadership in key states, with wholesale share above 20% in IL/PA) over time could lead to a premium over peers, in our view… As we project into 4Q, we model at least the same share levels per state in 3Q plus underlying market growth. In CA the company is gaining share per store (existing customers) as well as adding new retail customers.”These comments back up Zuanic’s Overweight (i.e. Buy) rating. His price target, of $18, indicates confidence in 77% growth potential for next year. With 5 Buy reviews overbalancing a single Hold, Cresco is our third Strong Buy cannabis stock. At a current trading price of $10.12, the $14.61 average price target gives a one-year upside of 44%. (See Cresco’s stock analysis on TipRanks)To find good ideas for cannabis stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

[itswallstreetpr]

Five Pot Stocks with Next Level Potential (CGC, HRVSF, NUGS, CRLBF, TLRY)

The action is heating back up in the cannabis patch. Bigtime. Investors have been taught to sit on the sidelines in these stocks because “they keep going down”. That’s what happens in a bear market. These stocks got too far ahead of themselves a couple years ago, and we were seeing ridiculous valuations on a price-to-sales basis, and fears of a supply glut destroying the cannabis pricing market on a commodity level. We saw stocks in this space trading at 50x sales. But, fast forward about 18 months, and you have absurdity in the other direction. Investors have been taught to doubt pot stocks – taught they were a sucker’s bet. And they learned that lesson so well that you are now living in a world where a company making hundreds of millions of dollars a quarter can post 430% growth and still trade at 1.8x sales. Of course, it’s not just about the big names. There is a real narrative of entrepreneurial success going on here as well. Companies are solving problems and providing a strong product to an end market with seemingly bottomless demand. One big key is that we are now starting to see many of the high-growth cannabis stocks ramping above their 50-day moving averages as a group. That hasn’t happened in nearly two years, and it represents a strong signal – along with the valuation metrics – that we are now in a new cyclical cannabis bull market inside of the larger secular cannabis bull. With that in mind, we have picked out a selection of some of the most interesting names in the space for your consideration: Canopy Growth Corp (NYSE:CGC), Harvest Health & Recreation Inc (OTCMKTS:HRVSF), Cannabis Strategic Ventures (OTCMKTS:NUGS), Cresco Labs Inc (OTCMKTS:CRLBF), and Tilray Inc (NASDAQ:TLRY),.   Canopy Growth Corp (NYSE:CGC) engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. It’s perhaps the biggest overall name in the space when it comes to a combination of producing and investing in the space, so it has to be near the top of any measure as far as benefitting from a shift whereby full-scale legalization in the US market is concerned. According to its own materials, the company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, Bedrocan Canada, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands. This is also one of the most geographically diversified players in the cannabis space, with operations in 12 countries across five continents. One of its most important divestitures and strategic interests is Canopy Rivers Inc., a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. The company works collaboratively with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. If you're long this stock, then you're liking how the stock has responded to the announcement. CGC shares have been moving higher over the past week overall, pushing about 8% to the upside on above average trading volume. Canopy Growth Corp (NYSE:CGC) pulled in sales of $123.8M in its last reported quarterly financials, representing top line growth of 49%. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($2.3B against $418.3M).   Harvest Health & Recreation Inc (OTCMKTS:HRVSF) bills itself as a company that cultivates, manufactures, and retails cannabis in the United States. The company just announced plans to divest select retail assets in California to Hightimes Holding Corp. Harvest and its affiliates intend to sell a portfolio of equity and assets with respect to 13 operational and planned dispensaries in California for total consideration including up to $5 million in cash, $7.5 million as a one-year promissory note with 10% interest, and $67.5 million in Series A Preferred Stock issued by High Times. Harvest will retain select retail dispensaries and licenses for potential retail locations in California following completion of this transaction. That news has helped to drive a major rip in the stock, but it doesn’t suggest clear value other than by reducing the burden of some likely difficult leverage levels. Harvest Health & Recreation Inc. is one of the first consistently profitable, vertically integrated cannabis companies with one of the largest footprints in the U.S. Harvest’s complete vertical solution includes industry-leading cultivation, manufacturing, and retail facilities, construction, real estate, technology, operational, and brand building expertise — leveraging in-house legal, HR and marketing teams, along with proven experts in writing and winning state-based applications. The company has more than 525 employees with proven experience, expertise and knowledge of in-house best practices that are drawn upon whenever Harvest enters new markets. Harvest’s executive team is comprised of leaders in finance, compliance, real estate and operations. Harvest Health & Recreation Inc (OTCMKTS:HRVSF) managed to rope in revenues totaling $49.9M in overall sales during the company's most recently reported quarterly financial data -- a figure that represents a rate of top line growth of 123%, as compared to year-ago data in comparable terms. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($39.8M against $76.9M, respectively).   Cannabis Strategic Ventures (OTCMKTS:NUGS) is one of the largest publicly traded marijuana cultivators in the United States, and a rapidly growing story on the California cannabis scene. The company just announced that it has seen record total monthly cannabis sales and record sequential monthly cannabis sales growth so far in the month of April, with total gross cannabis sales for April running at an annualized pace of more than $6 million, up more than 400% over average monthly sales seen in calendar Q1. “This data should help to better contextualize our prior announcement detailing our expansion in total cannabis production capacity,” commented Simon Yu, CEO of Cannabis Strategic Ventures. “Demand is through the roof. We don’t see this as a consequence of the stay-at-home policy. This is about improving market positioning in a strong structural growth boom. We are establishing a wider and wider footprint in terms of distribution partners, and the overall market is continuing to experience powerful growth in demand at the end market level.” In other words, this is a new high-growth name in the space that is just starting to put up tangible signs of major traction in the California cannabis market, which is the largest marketplace on the planet for weed. And the fact that NUGS just pushed up its production capacity should suggest that this sudden explosion in growth is likely to continue in May and June and possibly through the rest of the year. That’s probably why we are starting to see the smart money move into shares of the stock over recent days.   Cresco Labs Inc (OTCMKTS:CRLBF) trumpets itself as a company that manufactures and sells medical cannabis products in the United States. It offers cannabis dry flower; vaporizer forms of cannabis; cannabis oil in capsule, oral and sublingual solutions; cannabis in topical; and other cannabis products. The company also provides cannabis infused edibles, including chocolate and toffee confections, fruit-forward gummies, and hard sweet and chews. Cresco Labs Inc. sells its products under the Cresco brand. In addition, it operators a Hope Heal Health dispensary in Fall River, Bristol County, Massachusetts. Traders will note 51% piled on for shareholders of the stock during the past month. CRLBF has witnessed a pop in interest, as transaction volume levels have recently pushed 56% beyond its prior sustained average level. Cresco Labs Inc (OTCMKTS:CRLBF) managed to rope in revenues totaling $47.8M in overall sales during the company's most recently reported quarterly financial data -- a figure that represents a rate of top line growth of 0%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($108.2M against $60.6M).   Tilray Inc (NASDAQ:TLRY) engages in the research, cultivation, processing, and distribution of medical cannabis. This is one of the highest profile names in the space. But if you look under the surface, it may also be the weakest because of the crushing burden of its debt-servicing costs at this point. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. was incorporated in 2018 and is headquartered in Nanaimo, Canada. One of its key subsidiaries is High Park, which was launched to produce and distribute world-class cannabis brands and products for the Canadian market. Based in Toronto and led by a team with deep experience in cannabis and global consumer brands, High Park has secured the exclusive rights to produce and distribute a broad-based portfolio of cannabis brands and products in Canada, subject to applicable laws and regulations. And the stock has been acting well over recent days, up something like 18% in that time. Shares of the stock have powered higher over the past month, rallying roughly 36% in that time on strong overall action. Tilray Inc (NASDAQ:TLRY) generated sales of $46.9M, according to information released in the company's most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of -8.2% on the top line. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($96.8M against $92.4M). Read the full article

[grizzlemedia-blog]

Its Official: Origin House Is Now Part of Cresco Labs

Investors who purchased Origin House when the deal terms were renegotiated by Cresco Labs (CSE: CL) would be sitting on solid gains today. #marijuanastocks #potstocks $CL Read the full article

[capital10x]

Property Sale Should Make Cresco Stock A Buy...Eventually

Cresco Labs (CSE: CL.CN) remains a long-term buy, but the equity's downward slide and the reaction to the property sale indicate investors should wait to buy Cresco. #marijuanastocks #potstocks $CL Read the full article

[managermint]

Motley Fool: Origin House's Revenue Skyrockets as the California Cannabis Market Gains Momentum

Motley Fool: Origin House’s Revenue Skyrockets as the California Cannabis Market Gains Momentum

Investors have become accustomed to Origin House (OTC:ORHOF) delivering sizzling revenue growth. In May, for example, the cannabis brands and distribution company reported a 41% quarter-over-quarter sales increase in the first quarter.

But has Origin House kept the impressive momentum going? The company answered with a resounding “yes” with its second-quarter results announced before the market…

[otcwiki]

CRLBF

Cresco Labs conducts its business operations and ensures efficiency in service delivery together with its subsidiaries. The company offers quality, consistent, and approachable cannabis products tailored to the customer's needs. Moreover, the company presents the common stock under the name CRLBF Stock.

[gjupdates]

Is Cresco Labs a Buy?

[ad_1] Cresco Labs (CRLBF -2.25%) is one of the leading companies in the marijuana industry. However, the share price of the multi-state operator has crashed by 75% over the past 12 months as the excitement the industry once enjoyed looks to be long gone. Is this an opportunity for investors, or are they better off avoiding Cresco Labs? Cresco has been struggling to generate growth When Cresco…

[moneygigs]

Is Cresco Labs a Buy?

Cresco Labs (CRLBF -2.25%) is one of the leading companies in the marijuana industry. However, the share price of the multi-state operator has crashed by 75% over the past 12 months as the excitement the industry once enjoyed looks to be long gone. Is this an opportunity for investors, or are they better off avoiding Cresco Labs? Cresco has been struggling to generate growth When Cresco Labs last…

[itswallstreetpr]

Who Will Lead the Hemp-related Space in 2020? (TCNNF, ACB, TMGI, CRLBF)

The time is coming when the cannabis and hemp stocks are back in gear. That means it’s time for investors to start making a shopping list based on what’s likely to work best in the space around the next corner. With that in mind, we present our shopping list drawn from relative strength, breadth of resources, top talent, and recent catalysts: Trulieve Cannabis Corp (OTCMKTS:TCNNF), Aurora Cannabis Inc (NYSE:ACB), Marquie Group Inc (OTCMKTS:TMGI), and Cresco Labs Inc (OTCMKTS:CRLBF).     Trulieve Cannabis Corp (OTCMKTS:TCNNF) is a clear relative strength leader that continues to expand its footprint. The company recently announced that it opened the doors of its latest Florida location on Tuesday, November 26th, in Lakeland. The Central Florida location is a milestone for Florida's largest operator as Trulieve becomes the first operator in Florida to reach 40 locations. "Trulieve has come a long way over the past three years – from closing out 2016 with only two stores to celebrating our record-breaking 40th store in Florida with even more to come in 2019 — and 2020 – as we continue to strategically plan for the future," said Trulieve CEO Kim Rivers. "As the patient registry continues to grow and Florida's residents continue to seek alternative, natural relief, we will continue our mission to expand access to the natural, effective, and safe medications they have come to rely on." Trulieve Cannabis Corp (OTCMKTS:TCNNF) promulgates itself as a company that, through its subsidiary, Trulieve, Inc., engages in the cultivation, possession, distribution, and sale of medical cannabis in the United States. It offers a suite of Trulieve branded products with approximately 125 SKUs, including nasal sprays, capsules, concentrates, syringes, and cannabis flower in tamper-proof containers for vaporizers, topical creams, tinctures, and vape cartridges. The company distributes its products to Trulieve branded stores (dispensaries) in Florida, as well as takes orders online and by phone for delivery. As of November 20, 2018, the company operated 21 dispensaries. Trulieve Cannabis Corp. is headquartered in Quincy, Florida. According to company materials, “Trulieve is a vertically integrated "seed to sale" company and is the first and largest fully licensed medical cannabis company in the State of Florida. Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve branded stores (dispensaries) throughout the State of Florida, as well as directly to patients via home delivery. Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL.” Even in light of this news, TCNNF has had a rough past week of trading action, with shares sinking something like -9% in that time. That said, chart support is nearby and we may be in the process of constructing a nice setup for some movement back the other way. Shares of the stock have powered higher over the past month, rallying roughly 14% in that time on strong overall action. Trulieve Cannabis Corp (OTCMKTS:TCNNF) generated sales of $93.4M, according to information released in the company's most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of 20.5% on the top line. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($41.1M against $64.9M, respectively).     Aurora Cannabis Inc (NYSE:ACB) is a member of the so-called “old guard” of the cannabis space, with a huge footprint, but a continuing bent toward innovation in the space, and the resources to keep the company out in front of the pack as the next leg gets underway. To that end, the company just announced that one of the Company's oil products has now been approved for use under Ireland's new Medical Cannabis Access Programme (MCAP). According to the release, Aurora's High CBD Oil Drops received approval from the Irish authorities and have now been added to a regulatory schedule by the Irish Minister of Health enabling importation, prescribing and supply under the scheme and is to date, one of only two products to gain such authorization. Dr Shane Morris , Chief Product Officer at Aurora said, "Aurora is pleased to be able to assist patients who are seeking treatment with high quality EU-GMP (good manufacturing practice) certified pharmaceutical-grade medical cannabis in Ireland.   We are very proud to be one of the first approved suppliers of medical cannabis under the MCAP.  We want to acknowledge the efforts made by many people, especially the patients and doctors who have campaigned for access to these medicines.  We look forward to more of Aurora's high-quality medicines being approved, so that more patients can benefit from the MCAP in Ireland.  We will continue to work closely with all parties and state agencies to facilitate further availability." Aurora Cannabis Inc (NYSE:ACB) is one of the most widely diversified players in the cannabis space due to its powerful strategic investments. However, just drilling down into its core cannabis production operations, Aurora Cannabis Enterprises Inc, trumpets itself as “one of the world’s largest and leading cannabis companies” and a licensed producer of medical cannabis pursuant to ACMPR. We would expect expansion on the way given the inflow of investment capital. But, at present, the Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, known as Aurora Mountain, is currently constructing a second 800,000 square foot production facility, known as “Aurora Sky”, at the Edmonton International Airport, and has acquired, and is undertaking completion of a third 40,000 square foot production facility in Pointe-Claire, Quebec, on Montreal’s West Island. It will be interesting to see if the stock can break out of its recent sideways action. Over the past week, the stock is net flat, and looking for something new to spark things. Over the past month, shares of the stock have suffered from clear selling pressure, dropping by roughly -31%. Aurora Cannabis Inc (NYSE:ACB) managed to rope in revenues totaling $75.2M in overall sales during the company's most recently reported quarterly financial data -- a figure that represents a rate of top line growth of 153.6%, as compared to year-ago data in comparable terms. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($236.9M against $464.6M, respectively).     Marquie Group Inc (OTCMKTS:TMGI) is a clear emerging leadership play in the CBD space, so it deserves acknowledgement here in this group. While the stock hasn’t yet started to gain traction with traders, the company boasts top talent in the health and beauty space coming together with the concept of the huge growth anticipated in CBD. Much of that promise springs from its leader, Jacquie Carter Angell, who has established an internationally recognized personal brand as a beauty expert, appearing in television, radio, magazine, newspaper and media events around the world. According to the company, during that time, she has partnered with celebrities, Olympic athletes, doctors, nutritionists and Nobel Prize laureates in brand-building and marketing health and beauty products to women in more than 90 countries. “The CBD market has grown exponentially, evolving from the virtually unknown, to a marketplace where consumer perception and expectations are on the rise. A lesser-known fact is that the largest consumer for CBD products is women between 35-49 years of age,” commented Jacquie Carter Angell, President of The Marquie Group. “We have predicated the majority of the packaging, branding, marketing, and digital identity around this fact in a manner that positions Whim with far less direct niche-level competition than other CBD product brands.” Marquie Group Inc (OTCMKTS:TMGI) bills itself as company led by former Director of Worldwide Training and Education for Herbalife Nutrition, Jacquie Carter Angell. It is a direct-to-consumer health and beauty products platform with a pipeline of innovative solutions to pervasive wellness concerns: anxiety, anti-aging, low energy, sleeplessness, and stress that use advanced formulations of plant-based, amino-acids and CBD alternatives to chemical ingredients. All products will feature unique formulations of top-quality ingredients meant to impart skin health that comes from improved amino-acid balance and CBD nutrition. The Marquie Group owns and operates two businesses: Music of Your Life, Inc, the nation's longest-running, nationally syndicated music radio network broadcast nationwide and internationally to a worldwide audience on the Internet, and Global Nutrition Experience, Inc. (GNX), an intellectual property licensing and development corporation. Products planned for a 2020 launch include facial skin care serums, a powerful amino acid infused collagen drink and custom blended CBD tinctures each with their own potent puree of nature’s finest fruits, flowers and herbs. Each one is uniquely developed to provide optimal sleep and relaxation, mental focus and clarity or beauty and antioxidant benefits via an array of plant- based ingredients formulated to enhance one's Inner Health and Outer Beauty.     Cresco Labs Inc (OTCMKTS:CRLBF) is suddenly back on the radar as a deep value slash growth play in the cannabis patch following the stock’s dramatic turnaround in December. To add some further color to the story, the company just announced that it has completed its first harvest from its expanded cultivation facility in Lincoln, IL. According to the release, “With the recent growth of the state’s medical market and adult-use legalization going live on January 1st, Cresco has been scaling operations to be able to accommodate what is expected to be one of the largest cannabis markets in the country. As the only operator in Illinois with three (3) cultivation facilities, Cresco has a unique competitive advantage and is positioned to build on its already market-leading position.” CRESCO LABS ORD (OTCMKTS:CRLBF) trumpets itself as a company that manufactures and sells medical cannabis products in the United States. It offers cannabis dry flower; vaporizer forms of cannabis; cannabis oil in capsule, oral and sublingual solutions; cannabis in topical; and other cannabis products. The company also provides cannabis infused edibles, including chocolate and toffee confections, fruit-forward gummies, and hard sweet and chews. Cresco Labs Inc. sells its products under the Cresco brand. In addition, it operators a Hope Heal Health dispensary in Fall River, Bristol County, Massachusetts. The company was formerly known as Cresco Labs, LLC and changed its name to Cresco Labs Inc. in November 2018. Cresco Labs Inc. is headquartered in Chicago, Illinois. According to the release, “Cresco Labs, based in Chicago, is a leading U.S. cannabis company with experienced management, access to capital and a demonstrated growth strategy. As a differentiated grower, processor and retailer of premium cannabis operating in ten states, the company focuses on entering highly regulated markets with outsized demand potential and high barriers to entry. Its impressive speed-to-market gives Cresco a distinct competitive advantage as it replicates its model to expand its national footprint. Cresco’s proven ability to execute is complemented by a cutting-edge brand strategy spearheaded by several of the brightest minds in consumer marketing in the nation. Cresco’s products are tailored to all major consumer segments: everyday cannabis, medicinally focused, connoisseur grade, and chef inspired edibles by James Beard Award-winning pastry chef Mindy Segal. Learn more about Cresco Labs at crescolabs.com.” The stock has been acting very well over recent days, up something like 32% in that time. Cresco Labs Inc (OTCMKTS:CRLBF) pulled in sales of $47.8M in its last reported quarterly financials, representing top line growth of 19.6%. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($108.2M against $60.6M). Read the full article